Devoted to the Pursuit of Clinical Excellence in Gastroenterology and Hepatology for Over 30 Years

  • Home

    • Contact Us
    • Privacy Policy
  • About

    • Membership
    • Board
    • Committees
  • 2022 GI Symposium

    • 2022 GI Sympo Sponsors
    • GI Symposium Abstract Submissions
    • Accreditation Information
  • 2022 Liver Symposium

    • Liver Symposium Abstract Submissions
    • COVID-19 Safety Precautions
    • 2022 Liver Registration
    • 2019 Abstract Awardees
  • 2021-2022 Webinar Series

    • 2020-2021 Webinar Series
  • Newsletter

  • Resources

    • 2022 Liver Symposium Resource
    • 2021 GI Symposium
    • 2021 Liver Symposium
    • 2020 GI Symposium
    • 2019 Liver Symposium
    • 2019 GI Symposium
    • 2018 Post-AASLD
    • 2018 Post-DDW
    • 2017 Post-AASLD
    • 2017 Post-DDW
    • 2016 Post-AASLD
    • 2016 Post-DDW
    • 2015 Post-AASLD
    • 2015 Post-DDW
    • 2014 Post-AASLD
  • Plans & Pricing

  •  

    Use tab to navigate through the menu items.
    Exelixis Unconfirmed.png

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

    Dave Schmahl

    (714) 620-9112

    dschmahl@exelixis.com

    www.Exelixis.com

    Photo- Dave Schmahl.jpg

    CONTACT

    Cabometyx Package Insert

     E: ncscg@pacemedcom.com   

    • LinkedIn Social Icon

     The NCSCG Society is managed by Pace Medical Communications